Company Overview and News

1
Accenture's Q3 2018 Results: A Company That Is Firing On All Cylinders

2018-07-05 seekingalpha
The company is firing on all cylinders and investors should expect for more of the same in the quarters ahead.
ITT ACN INOTF

101
The R.I.P. Portfolio: Q2 2018 Update

2018-07-04 seekingalpha
The portfolio has underperformed its benchmark so far in 2018, with General Electric being a significant contributor, but it is properly positioned to benefit from several major trends.
FB TWX UAA MET KEY BAC TWTR AAPL ACN INOTF CAH INTC BAC GEC GE C ITT BHGE SYF TWC UA BHI TGT GNE

0
'You can’t undo that damage': How safe is your health data?

2018-06-30 theage.com.au
For the next three months, Australians have the chance to stop the government creating a digital medical health record with their information.
ITT INOTF

0
'You can’t undo that damage': How safe is your health data?

2018-06-30 smh.com.au
For the next three months, Australians have the chance to stop the government creating a digital medical health record with their information.
ITT INOTF

0
BRIEF-Internet Of Things Received TSX Venture Approval For Joint Venture Agreement With New Hope Group

2018-04-13 reuters
* INTERNET OF THINGS INC. RECEIVED TSX VENTURE APPROVAL FOR JOINT VENTURE AGREEMENT WITH NEW HOPE GROUP Source text for Eikon: Further company coverage:
ITT INOTF

394
The R.I.P. Portfolio: Q1 2018 Update

2018-04-03 seekingalpha
This real-money portfolio was first introduced to the Seeking Alpha community in December 2015 and it outperformed its benchmark in each of the last two years.
BAC GEC GE C ITT TWX MET TWC DWDP BAC TWTR AAPL ACN INOTF GNE INTC

12
Everyone is a Closet Technician

2018-03-29 thereformedbroker
Everyone is a closet technician. Everyone. And in a panic or a market correction, this truism is even more, um, truistic.
MS.PRI ITT MS.PRK MS.PRE INOTF MS.PRF MS.PRG MS MS.PRA

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

15h - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

17h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to TSXV:ITT / Internet of Things Inc on message board site Silicon Investor.

Quitting Cigarettes Twitter, Inc.
MITT ROMNEY Weblogs and Twitter
Twitter Greenblattu0027s Little Book That Beats The Market
Light Emitting Devices, organic and novel Binary Options Brokers - So Many To Choose, So Little Are Le
Twitter Tweet from a Known Short On Twitter